PCN183 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet-Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in Canad ...
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.274
https://www.valueinhealthjournal.com/article/S1098-3015(21)00491-5/fulltext
Title :
PCN183 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet-Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in Canad ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00491-5&doi=10.1016/j.jval.2021.04.274
First page :
Section Title :
Open access? :
No
Section Order :
10849